SCHEMBL25447282

SCHEMBL25447282

CC(C)(C)OC(=O)N1CCc2nn(C3CCCCC3)cc2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
ESR2 Q92731 1/20 0.46
NR1H2 P55055 1/20 0.45
HPGDS O60760 1/20 0.41
SLC6A9 P48067 2/20 0.41
PDK2 Q15119 1/20 0.40
EPHX1 P07099 1/20 0.40
MAPK1 P28482 1/20 0.40
HPGD P15428 1/20 0.39
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
UCHL1 P09936 1/20 0.39
HCAR1 Q9BXC0 1/20 0.38
PIM1 P11309 1/20 0.38
MARK3 P27448 1/20 0.38
MAP4K2 Q12851 1/20 0.38
CAMK2B Q13554 1/20 0.38
PIM3 Q86V86 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
GCK P35557 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1016779 0.99 MAPT (0.48) MAPTESR2NR1H2HPGDSSLC6A9
SCHEMBL16210543 0.94 MAPT (0.50) MAPTESR2NR1H2HPGDSPDK2
SCHEMBL30793116 0.91 MAPT (0.43) MAPTESR2NR1H2HPGDSSLC6A9
SCHEMBL25447317 0.91 ESR2 (0.46) MAPTESR2NR1H2HPGDSSLC6A9
SCHEMBL25447281 0.90 MAPT (0.47) MAPTESR2NR1H2HPGDSPDK2
SCHEMBL30793206 0.90 ESR2 (0.44) MAPTESR2NR1H2HPGDSSLC6A9
SCHEMBL20792883 0.89 MAPT (0.46) MAPTESR2NR1H2HPGDSPDK2
SCHEMBL23794809 0.86 MAPT (0.47) MAPTESR2NR1H2HPGDSPDK2
SCHEMBL23852158 0.84 MAPT (0.46) MAPTESR2NR1H2HPGDSPDK2
SCHEMBL25172514 0.83 MAPT (0.55) MAPTESR2NR1H2HPGDSDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230145336-A1 BRAF DEGRADERS BRAF, NRAS, RAF1 MAPT 2440/4885ESR2 2614/4885NR1H2 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.